Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:35 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

NCT02174731
View directory record Official record
Conditions
Anemia
Interventions
Roxadustat, Epoetin alfa
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
51
States / cities
Huntsville, Alabama • El Centro, California • Fairfield, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 3, 2026, 5:35 AM EST
Completed Not applicable Interventional Results available

Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II

NCT04669301
View directory record Official record
Conditions
Cancer-related Problem/Condition, Cognitive Impairment
Interventions
MAAT-G, Supportive therapy (time and attention control)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 3, 2026, 5:35 AM EST
Completed Not applicable Interventional

The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population

NCT01407419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Treatment Acceleration, Monthly Assessment
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer

NCT00004087
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

NCT05320393
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
Drug
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

NCT02891226
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Tucson, Arizona • Garden Grove, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection

NCT01972334
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
FMT, placebo
Biological
Lead sponsor
MemorialCare Health System
Other
Eligibility
1 Year to 21 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

NCT02057263
View directory record Official record
Conditions
Hepatitis B
Interventions
Alendronate, Hepatitis B Vaccine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

NCT01742221
View directory record Official record
Conditions
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions
HemaMax, Placebo
Biological · Drug
Lead sponsor
Neumedicines Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03430011
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JCARH125, JCARH125 + anakinra
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2 Interventional Results available

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

NCT00486278
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
Interventions
eptacog alfa (activated), vatreptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Nov 3, 2026, 5:35 AM EST
Completed Not applicable Interventional Results available

The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension

NCT00979732
View directory record Official record
Conditions
Hypertension
Interventions
grape seed extract, grape seed extract placebo
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
25 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 3, 2026, 5:35 AM EST
Completed No phase listed Observational

Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

NCT04207099
View directory record Official record
Conditions
Non Healing Diabetic Foot Ulcer
Interventions
MolecuLight i:X Imaging Device
Device
Lead sponsor
MolecuLight Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Vista, California • Lake Success, New York • Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2 Interventional Results available

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

NCT00321932
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 2 Interventional Results available

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

NCT04632225
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Engensis, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

NCT02330653
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Fecal Microbiota Transplant (FMT), Placebo
Biological
Lead sponsor
Stacy A. Kahn
Other
Eligibility
5 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain

NCT00178945
View directory record Official record
Conditions
Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS), Cervical Dystonia
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Nov 3, 2026, 5:35 AM EST
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

NCT05227001
View directory record Official record
Conditions
Influenza, Human
Interventions
PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 3, 2026, 5:35 AM EST
Completed Phase 3 Interventional Results available

Dysport® Adult Lower Limb Spasticity Study

NCT01249404
View directory record Official record
Conditions
Leg Spasticity
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Nov 3, 2026, 5:35 AM EST
Terminated Phase 4 Interventional Results available

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

NCT03078270
View directory record Official record
Conditions
Anxiety Disorder Social, Anxiety
Interventions
botulinum toxin A, Placebo
Drug · Other
Lead sponsor
Daniel Lieberman
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Nov 3, 2026, 5:35 AM EST